
Teleflex (TFX) Stock Forecast & Price Target
Teleflex (TFX) Analyst Ratings
Bulls say
Teleflex is a growing medical technology company with strong financial performance and a commitment to shareholder value. Although there may be some challenges in the near term, the company's focus on sustainable growth and cost savings, as well as strategic M&A and returning cash to shareholders, suggest a positive outlook for the company's stock. The potential for divestitures and a diverse product portfolio also adds to the long-term growth potential for investors.
Bears say
Teleflex is facing potential downside risks, as the company's plans to unlock value through a spin-off or sale of several business lines may not go as planned. Additionally, there may be challenges in executing the company's growth and margin profile assumptions, leading to limited upside potential. The recent portfolio moves, including acquisitions and divestitures, could result in uncertainty in the near-to-intermediate term. The incoming CEO brings MedTech leadership experience and returns TFX to its growth focus, but the company may face slower-than-expected adoption of key products, resulting in low-single digit growth and margin deterioration. In a downside scenario, the stock could reach $80 per share, while in the base case, the stock has a 12-month price target of $138.
This aggregate rating is based on analysts' research of Teleflex and is not a guaranteed prediction by Public.com or investment advice.
Teleflex (TFX) Analyst Forecast & Price Prediction
Start investing in Teleflex (TFX)
Order type
Buy in
Order amount
Est. shares
0 shares